Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big potential implications for novel oral anticoagulants.
Researchers from across the biomedical research community met in October to discuss solutions to the 'irreproducibility epidemic', which has been re-emphasized by new data from Novartis and Sigma-Aldrich.
The Innovative Medicines Initiative's DRIVE-AB project joins the fray of task forces working to reinvigorate interest in antibiotics by developing reimbursement models that delink revenue from sales volume.
Recent results have cast doubt over how effective a breakthrough class of cystic fibrosis drugs can be in patients with the most common form of the disease.
The European Investment Bank has invested €75 million in a risk-sharing drug development deal with the pharmaceutical company UCB, potentially opening up a new source of research and development (R&D) funding.
Pirfenidone and nintedanib look set to become the first drugs approved in the United States for idiopathic pulmonary fibrosis, paving a drug development path for more treatments for this deadly disease.
The US National Cancer Institute is launching an 'exceptional responder' programme to see whether outliers from failed cancer trials can open up new drug development avenues.